Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 2, 2009, Pages 370-375

  Li, Su xia ^a   Zou, Yan ^b   Liu, Li jing ^a   Wu, Ping ^a   Lu, Lin ^a  

^a PEKING UNIVERSITY   (China)

^b NATIONAL RESEARCH INSTITUTE FOR FAMILY PLANNING   (China)

Author keywords

Aripiprazole; Conditioned preference place; Dopamine; Morphine; Reinstatement; Serotonin

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; MORPHINE; NEUROLEPTIC AGENT; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG DEPENDENCE; DRUG MECHANISM; LIMBIC CORTEX; LOCOMOTION; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; RELAPSE; SEROTONIN RELEASE; SINGLE DRUG DOSE;

ANIMALS; CONDITIONING, CLASSICAL; MALE; MORPHINE; PIPERAZINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 59749106374     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.01.014     Document Type: Article

References (77)

1. Anton R.F., Kranzler H., Breder C., Marcus R.N., Carson W.H., and Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 28 (2008) 5-12
2. Arnold K.K., and Yager J. A case of unexpected and selective remission of a 20-year history of ephedrine dependence following treatment with low-dose aripiprazole. J Clin Psychiatry 68 (2007) 1620-1621
3. Assie M.B., Ravailhe V., Faucillon V., and Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315 (2005) 265-272
4. Bowles T.M., and Levin G.M. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 37 (2003) 687-694
5. Bozarth M.A., and Wise R.A. Heroin reward is dependent on a dopaminergic substrate. Life Sci 29 (1981) 1881-1886
6. Carson W.H., and Kitagawa H. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol Bull 38 (2004) 38-45
7. Childress A.R., Ehrman R., McLellan A.T., MacRae J., Natale M., O, and Brien C.P. Can induced moods trigger drug-related responses in opiate abuse patients?. J Subst Abuse Treat 11 (1994) 17-23
8. Comer S.D., and Carroll M.E. Oral caffeine pretreatment produced modest increases in smoked cocaine self-administration in rhesus monkeys. Psychopharmacology (Berl) 126 (1996) 281-285
9. Davies M.A., Sheffler D.J., and Roth B.L. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 10 (2004) 317-336
10. Dolberg O.T., Iancu I., Sasson Y., and Zohar J. The pathogenesis and treatment of obsessive-compulsive disorder. Clin Neuropharmacol 19 (1996) 129-147
11. Ettenberg A., Pettit H.O., Bloom F.E., and Koob G.F. Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Psychopharmacology (Berl) 78 (1982) 204-209
12. Feltenstein M.W., Altar C.A., and See R.E. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry 61 (2007) 582-590
13. Gal K., and Gyertyan I. Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats. Brain Res Bull 61 (2003) 595-601
14. Gerrits M.A., and Van Ree J.M. Effect of nucleus accumbens dopamine depletion on motivational aspects involved in initiation of cocaine and heroin self-administration in rats. Brain Res 713 (1996) 114-124
15. Grunder G., Carlsson A., and Wong D.F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60 (2003) 974-977
16. Hirose T., Uwahodo Y., Yamada S., Miwa T., Kikuchi T., and Kitagawa H. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 18 (2004) 375-383
17. Ingman K., Kupila J., Hyytia P., and Korpi E.R. Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol 41 (2006) 391-398
18. Janiri L., Martinotti G., and Di Nicola M. Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: results from a pilot study. J Clin Psychopharmacol 27 (2007) 519-520
19. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., and Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441 (2002) 137-140
20. Kleven M.S., Barret-Grevoz C., Bruins Slot L., and Newman-Tancredi A. Novel antipsychotic agents with 5-HT1A agonist properties: role of 5-HT1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49 (2005) 135-143
21. Koob G.F., Carrera M.R.A., Gold L.H., Heyser C.J., Maldonado-Irizarry C., and Markou A. Substance dependence as a compulsive behavior. J Psychopharmacol 12 (1998) 39-48
22. Kranzler H.R., Covault J., Pierucci-Lagha A., Chan G., Douglas K., and Arias A.J. Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res 32 (2008) 573-579
23. Langlois X., Te Riele P., and Ashton D. In vivo receptor occupancy profile of aripiprazole in rat brain. Soc Neurosci Abstr 31 (2005) 444-573
24. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
25. Leite J.V., Guimaraes F.S., and Moreira F.A. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 578 (2008) 222-227
26. Levoyer D., Drapier D., Fadier-Salice G., and Millet B. [Clinical impact of aripiprazole in patients suffering from schizophrenia]. Encephale 33 (2007) 332-338
27. Li Z., Ichikawa J., Dai J., and Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493 (2004) 75-83
28. Lile J.A., Stoops W.W., Vansickel A.R., Glaser P.E., Hays L.R., and Rush C.R. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology 30 (2005) 2103-2114
29. Lu L., Liu D., Ceng X., and Ma L. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 12 (2000) 4398-4404
30. Lu L., Xu N.J., Ge X., Yue W., Su W.J., Pei G., et al. Reactivation of morphine conditioned place preference by drug priming: role of environmental cues and sensitization. Psychopharmacology (Berl) 159 (2002) 125-132
31. Lu L., Liu Z., Huang M., and Zhang Z. Dopamine-dependent responses to cocaine depend on corticotropin-releasing factor receptor subtypes. J Neurochem 84 (2003) 1378-1386
32. Lu L., Shepard J.D., Hall F.S., and Shaham Y. Effect of environmental stressors on opiate and psychostimulant reinforcement, reinstatement and discrimination in rats: a review. Neurosci Biobehav Rev 27 (2003) 457-491
33. Ma Y.Y., Chu N.N., Guo C.Y., Han J.S., and Cui C.L. NR2B-containing NMDA receptor is required for morphine-but not stress-induced reinstatement. Exp Neurol 203 (2007) 309-319
34. Mackey W.B., and van der Kooy D. Neuroleptics block the positive reinforcing effects of amphetamine but not of morphine as measured by place conditioning. Pharmacol Biochem Behav 22 (1985) 101-105
35. Maes M., Meltzer H.Y., D, Hondt P., Cosyns P., and Blockx P. Effects of serotonin precursors on the negative feedback effects of glucocorticoids on hypothalamic-pituitary-adrenal axis function in depression. Psychoneuroendocrinology 20 (1995) 149-167
36. Markou A., Kosten T.R., and Koob G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18 (1998) 135-174
37. Martinotti G., Di Nicola M., and Janiri L. Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse 33 (2007) 393-401
38. Mutschler N.H., and Bergman J. Effects of chronic administration of the D1 receptor partial agonist SKF 77434 on cocaine self-administration in rhesus monkeys. Psychopharmacology (Berl) 160 (2002) 362-370
39. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., and Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31 (2006) 1854-1863
40. Nordquist R.E., Risterucci C., Moreau J.L., von Kienlin M., Kunnecke B., Maco M., et al. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology 54 (2008) 405-416
41. O Brien C.P. A range of research-based pharmacotherapies for addiction. Science 278 (1997) 66-70
42. O Brien C.P., Childress A.R., Ehrman R., and Robbins S.J. Conditioning factors in drug abuse: can they explain compulsion?. J Psychopharmacol 12 (1998) 15-22
43. Ohlsen R.I., and Pilowsky L.S. The place of partial agonism in psychiatry: recent developments. J Psychopharmacol 19 (2005) 408-413
44. Pettit H.O., Ettenberg A., Bloom F.E., and Koob G.F. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology (Berl) 84 (1984) 167-173
45. Pilla M., Perachon S., Sautel F., Garrido F., Mann A., Wermuth C.G., et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400 (1999) 371-375
46. Pulvirenti L., Balducci C., Piercy M., and Koob G.F. Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat. J Pharmacol Exp Ther 286 (1998) 1231-1238
47. Roberts D.C.S., and Vickers G. Atypical neuroleptics increase self-administration of cocaine: an evaluation of a behavioural screen for antipsychotic activity. Psychopharmacology (Berl) 82 (1984) 135-139
48. Robinson T.E., and Berridge K.C. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 Suppl 2 (2000) S91-117
49. Schwabe K., and Koch M. Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats. Psychopharmacology (Berl) 191 (2007) 759-765
50. Shaham Y., Shalev U., Lu L., De Wit H., and Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168 (2003) 3-20
51. Shalev U., Grimm J.W., and Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 54 (2002) 1-42
52. Smith J.E., Guerin G.F., Co C., Barr T.S., and Lane J.D. Effects of 6-OHDA lesions of the central medial nucleus accumbens on rat intravenous morphine self-administration. Pharmacol Biochem Behav 23 (1985) 843-849
53. Smith J.E., Shultz K., Co C., Goeders N.E., and Dworkin S.I. Effects of 5,7-dihydroxytryptamine lesions of the nucleus accumbens on rat intravenous morphine self-administration. Pharmacol Biochem Behav 26 (1987) 607-612
54. Sorensen G., Sager T.N., Petersen J.H., Brennum L.T., Thogersen P., Hee Bengtsen C., et al. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Psychopharmacology (Berl) 199 (2008) 37-46
55. Spampinato U., Esposito E., Romandini S., and Samanin R. Changes of serotonin and dopamine metabolism in various forebrain areas of rats injected with morphine either systemically or in the raphe nuclei dorsalis and medianus. Brain Res 328 (1985) 89-95
56. Spyraki C., Fibiger H.C., and Phillips A.G. Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology (Berl) 79 (1983) 278-283
57. Spyraki C., Nomikos G.G., Galanopoulou P., and Daifotis Z. Drug-induced place preference in rats with 5,7-dihydroxytryptamine lesions of the nucleus accumbens. Behav Brain Res 29 (1988) 127-134
58. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 1: "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 62 (2001) 841-842
59. Stoops W.W. Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine. Exp Clin Psychopharmacol 14 (2006) 413-421
60. Stoops W.W., Lile J.A., Glaser P.E., and Rush C.R. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend 84 (2006) 206-209
61. Stoops W.W., Lile J.A., Lofwall M.R., and Rush C.R. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. Am J Drug Alcohol Abuse 33 (2007) 769-776
62. Tao R., and Auerbach S.B. Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain. Neuroscience 68 (1995) 553-561
63. Tiihonen J., Kuoppasalmi K., Fohr J., Tuomola P., Kuikanmaki O., Vorma H., et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 164 (2007) 160-162
64. Unnithan S., Gossop M., and Strang J. Factors associated with relapse among opiate addicts in an out-patient detoxification programme. Br J Psychiatry 161 (1992) 654-657
65. Ventura R., Alcaro A., and Puglisi-Allegra S. Prefrontal cortical norepinephrine release is critical for morphine-induced reward, reinstatement and dopamine release in the nucleus accumbens. Cereb Cortex 15 (2005) 1877-1886
66. Wang J., Fang Q., Liu Z., and Lu L. Region-specific effects of brain corticotropin-releasing factor receptor type 1 blockade on footshock-stress- or drug-priming-induced reinstatement of morphine conditioned place preference in rats. Psychopharmacology (Berl) 185 (2006) 19-28
67. Wang X.Y., Zhao M., Ghitza U.E., Li Y.Q., and Lu L. Stress impairs reconsolidation of drug memory via glucocorticoid receptors in the basolateral amygdala. J Neurosci 28 (2008) 5602-5610
68. Warsi M., Sattar S.P., Bhatia S.C., and Petty F. Aripiprazole reduces alcohol use. Can J Psychiatry 50 (2005) 244
69. Wee S., Wang Z., Woolverton W.L., Pulvirenti L., and Koob G.F. Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology 32 (2007) 2238-2247
70. Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr Opin Pharmacol 5 (2005) 9-19
71. White F.J., and Kalivas P.W. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 51 (1998) 141-153
72. Wise R.A., Leone P., Rivest R., and Leeb K. Elevations of nucleus accumbens dopamine and DOPAC levels during intravenous heroin self-administration. Synapse 21 (1995) 140-148
73. Zhai H.F., Zhang Z.Y., Zhao M., Qiu Y., Ghitza U.E., and Lu L. Conditioned drug reward enhances subsequent spatial learning and memory in rats. Psychopharmacology (Berl) 195 (2007) 193-201
74. Zhai H., Wu P., Xu C., Liu Y., and Lu L. Blockade of cue- and drug-induced reinstatement of morphine-induced conditioned place preference with intermittent sucrose intake. Pharmacol Biochem Behav 90 (2008) 404-408
75. Zhang H.T. [Regulation of the central opioidergic nervous system on the emotional state of anxiety and its possible mechanisms]. Sheng Li Ke Xue Jin Zhan 28 (1997) 41-44
76. Zhou L.F., and Zhu Y.P. Changes of CREB in rat hippocampus, prefrontal cortex and nucleus accumbens during three phases of morphine induced conditioned place preference in rats. J Zhejiang Univ Sci B 7 (2006) 107-113
77. Zocchi A., Fabbri D., and Heidbreder C.A. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 387 (2005) 157-161